The Loudest Voice in Oncology Might Be Uncredentialed.

The Loudest Voice in Oncology Might Be Uncredentialed.

One Idea Worth Acting On.

A groundbreaking Phase 3 oncology trial reads out at a major medical congress.

Within minutes, a summary appears online.

It is not posted by the lead investigator.

It is posted by a digital influencer with fifty thousand followers who has misread the safety data.

Before the company's press release hits the wire, the market has already decided what the trial means.

What's Actually Happening

Historically, Medical Affairs and Scientific Communications built their strategies around credentialed KOLs, peer-reviewed journals, and congress podium presentations. The assumption was that expertise controlled the flow of scientific information.

That world no longer exists.

As Dr. Robert Matheis, President and CEO of ISMPP and contributor to Voices of Oncology, explains: digital opinion leaders may be entirely uncredentialed in the areas they discuss, yet they accumulate enormous visibility and credibility online. The internet does not distinguish between expertise and amplification.

A DOL with a large following who posts a simplified — or incorrect — interpretation of your data will often reach more oncologists, patients, and investors than the company's official press release. And they will reach them first.

Why This Matters

Misinformation travels faster than peer-reviewed science. In oncology, where patients are searching desperately for information about their disease and their options, the consequences are direct and serious.

As Elizabeth Franklin, Head of US Public Affairs and Patient Advocacy at Sanofi and contributor to Voices of Oncology, describes: a patient searching for information about their diagnosis can be overwhelmed by conflicting and frightening online content before they ever speak to a physician. The clinical data exists. The accessible, accurate interpretation of that data often does not.

Once a misleading interpretation gains momentum online, correcting the narrative becomes exponentially harder. Physicians encounter the distorted version before seeing the publication. Investors react to viral narratives before understanding the science. The company's carefully constructed clinical story has already been replaced by someone else's version.

Where It Breaks in the Real World

A company spends years building a Scientific Communications Platform designed to establish a unified, credible voice. The platform is launched. The data is strong. The KOL endorsements are in place.

Three days after the first major congress presentation, the most widely shared summary of the trial's results is a tweet from an account the company has never heard of — and the tweet gets the primary endpoint wrong.

The company has no response protocol for social media. The Compliance team is unsure what engagement is permitted. By the time anything official is posted, the incorrect version has been retweeted thousands of times.

What Needs to Change

Digital channels are not optional extensions of the scientific communications strategy. They are now the primary environment where clinical narratives form.

Organizations need DOL monitoring as a standing function — knowing who is commenting on their data, what they are saying, and where their interpretations diverge from the intended message. They need pre-publication response frameworks so that when a mischaracterization appears, the corrective voice is ready.

Compliance concerns about digital engagement are real and manageable. The greater risk is silence — letting a narrative the company did not write define a therapy the company spent a decade developing.

The Bottom Line

If you do not shape your clinical narrative online, someone else will.

And they will do it faster, with fewer facts, to a larger audience.

Add Your Voice — Where are you seeing this? What's working — and what's not?